DIFFUSE MIDLINE GLIOMA, H3 K27-ALTERED
Clinical trials for DIFFUSE MIDLINE GLIOMA, H3 K27-ALTERED explained in plain language.
Never miss a new study
Get alerted when new DIFFUSE MIDLINE GLIOMA, H3 K27-ALTERED trials appear
Sign up with your email to follow new studies for DIFFUSE MIDLINE GLIOMA, H3 K27-ALTERED, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
By submitting, you agree to our Terms of use
-
New hope for kids with relapsed cancers: experimental drug CBL0137 enters trials
Disease control Recruiting nowThis study tests an experimental drug called CBL0137 in children and young adults (ages 1 to 21) whose solid tumors, brain tumors, or lymphoma have returned or stopped responding to standard treatments. The goal is to find the safest dose and see if the drug can shrink tumors by …
Matched conditions: DIFFUSE MIDLINE GLIOMA, H3 K27-ALTERED
Phase: PHASE1, PHASE2 • Sponsor: Children's Oncology Group • Aim: Disease control
Last updated May 13, 2026 15:58 UTC
-
Targeted radiation shows promise for aggressive brain tumors in early trial
Disease control Recruiting nowThis study tests a new radioactive drug, 177Lu-PSMA-617, to see if it is safe for people with a fast-growing type of brain tumor called IDH wild type glioma. The drug targets a protein (PSMA) found on these tumor cells and delivers radiation directly to them. About 20 adults whos…
Matched conditions: DIFFUSE MIDLINE GLIOMA, H3 K27-ALTERED
Phase: PHASE1 • Sponsor: Memorial Sloan Kettering Cancer Center • Aim: Disease control
Last updated Apr 29, 2026 15:01 UTC